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Triple-negative breast cancer (TNBC) represents 10% of all breast cancers and is a very heterogeneous disease. Globally,
women with TNBC have a poor prognosis, and the development of effective targeted therapies remains a real challenge.
Patient-derived xenografts (PDX) are clinically relevant models that have emerged as important tools for the analysis of drug
activity and predictive biomarker discovery. The purpose of this work was to analyze the molecular heterogeneity of a large
panel of TNBC PDX (n = 61) in order to test targeted therapies and identify biomarkers of response. At the gene expression
level, TNBC PDX represent all of the various TNBC subtypes identified by the Lehmann classification except for
immunomodulatory subtype, which is underrepresented in PDX. NGS and copy number data showed a similar diversity of
significantly mutated gene and somatic copy number alteration in PDX and the Cancer Genome Atlas TNBC patients. The genes
most commonly altered were TP53 and oncogenes and tumor suppressors of the PI3K/AKT/mTOR and MAPK pathways. PDX
showed similar morphology and immunohistochemistry markers to those of the original tumors. Efficacy experiments with PI3K
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androgen receptor; LST: large-scale state transitions; M: mesenchymal; METABRIC: Molecular Taxonomy of Breast Cancer International
Consortium; MFS: metastasis-free survival; MSL: mesenchymal stem-like; NGS: next-generation sequencing; PDX: patient-derived xenografts; PR:
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and MAPK inhibitor monotherapy or combination therapy showed an antitumor activity in PDX carrying genomic mutations of
PIK3CA and NRAS genes. TNBC PDX reproduce the molecular heterogeneity of TNBC patients. This large collection of PDX is a
clinically relevant platform for drug testing, biomarker discovery and translational research.
What’s new?
Triple-negative breast cancer (TNBC) is a highly heterogeneous disease in terms of molecular profile, histological features,
clinical behavior, and drug response. Several clinical trials have been conducted for targeted therapies, but only in unselected
TNBC patients, with disappointing results. This study shows that patient-derived xenografts (PDX) reproduce the molecular
heterogeneity of TNBC. The presented genomic analysis identifies several interesting targetable drivers, particularly in the PI3K
and MAPK pathways. PDX models provide a unique opportunity to test various treatments on individual tumors: already, two
specific inhibitors (dual PI3K/mTOR and MEK inhibitor) and their combination are providing encouraging results.
Introduction
Triple-negative breast cancer (TNBC) represents approxi-
mately 10% of all breast cancers.1 This disease is routinely
defined by lack of expression of estrogen receptor (ER), proges-
terone receptor (PR) and no surexpression of human epidermal
growth factor receptor 2 (ERBB2).2 Globally, women with
TNBC have a poor prognosis, particularly due to the absence of
targeted therapy.3 TNBC is a highly heterogeneous disease in
terms of histological features, clinical behavior, drug response
and molecular profile.4 Various studies have addressed the het-
erogeneity of TNBC in terms of gene expression.5–7 Lehman
et al. identified six classes of TNBC (BL1, basal-like 1; BL2,
basal-like2; IM, immunomodulatory; M, mesenchymal; MSL,
mesenchymal stem-like; and LAR, luminal androgen receptor)
characterized by alterations of specific pathways.6 Chemother-
apy is the main systemic treatment for TNBC, but fewer than
30% of patients with metastatic disease survive more than
5 years after the diagnosis and TNBC remains associated with a
poor prognosis. The identification of molecular alterations in
TNBC is essential in order to develop new biomarkers and to
identify therapeutic targets for this type of breast cancer. In
addition to TP53 alterations, TNBC also displays heterogeneity
in terms of somatic genomic alterations, as described in large
cohorts of breast cancer (Molecular Taxonomy of Breast Can-
cer International Consortium [METABRIC] and The Cancer
Genome Atlas [TCGA]).8,9 Nevertheless, some interesting tar-
getable drivers have been described in terms of significantly
mutated genes (SMG) or somatic copy number alteration
(SCNA) analysis profiles, particularly genes of the PI3K and
MAPK pathways. TNBC heterogeneity is not only confined to
genomic features but also concerns morphologic and immuno-
histochemical characteristics.10,11 Several clinical trials have
been conducted on targeted therapies in TNBC, but only in
unselected TNBC patients, with disappointing results.
This marked heterogeneity of TNBC probably represents
the main barrier for the implementation of personalized care
and the development of new targeted therapies. There is a
need for preclinical models that faithfully represent this het-
erogeneity. Patient-derived xenografts (PDXs) models are
robust preclinical models to test targeted therapies because
they conserve each patient’s molecular heterogeneity12 and
response to treatment.13 These models have emerged as an
important translational research tool to identify new treat-
ments and predictive biomarkers.14,15 PDX models provide
the unique opportunity to test and compare different treat-
ment and combinations of treatments on a patient’s tumor
without the limitations of clinical trials. We previously
showed, in a small series of TNBC PDX, morphological and
genomic fidelity between PDXs and matched patient’s tumor
and possibility to identify efficient treatment and predictive
biomarkers.16
In the present study, we describe a large cohort of clinically
annotated TNBC PDX with genomic, transcriptomic and
immunohistochemical data in order to test targeted therapies
adapted to specific tumor alterations.
Materials and Methods
Patients
Sixty-one PDXs were obtained from the engraftment of 150 early-
stage triple-negative breast tumors or axillary lymph node metas-
tases excised from patients between 2000 and 2017 with their
informed consent.17,18 Forty of the 61 established TNBC PDXs
were obtained from primary breast cancer, 19 were obtained from
residual disease after neoadjuvant chemotherapy and 2 were
obtained from primary axillary nodes (Supporting Information
Tables S1 and S2).
Forty-four PDX from other subtypes of breast cancer
observed at Institut Curie were also analyzed: 32 tumors with
expression of hormonal receptors (HR; ER+ and/or PR+) and
no amplification of HER2 (HER2−), five HR-positive (ER+
and/or PR+) tumors with amplification of HER2 (HER2+)
and seven HR-negative (ER− and PR−) tumors with amplifi-
cation of HER2 (HER2+). The characteristics of all tumors are
detailed in Supporting Information Table S3.
2 Molecular heterogeneity in TNBC PDX
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Xenograft
Sixty-one triple-negative tumors and 44 HR+ and/or HER2+
specimens were obtained from BC patients with their informed
consent. Tumor fragments were removed during surgery and
grafted into the interscapular fat pad of female Swiss nude mice
under anesthesia, as previously described.18 The experimental
protocol and animal housing were in accordance with institu-
tional guidelines as proposed by the French Ethics Committee
(Agreement B75-05-18, France). Two models with specific
genomic alterations were chosen for in vivo preclinical assays:
HBCx92 mice (with NRAS mutation) were treated with
selumetinib (50 mg/kg, bid) (MedChem Express®, Monmouth
Junction, NJ), five times a week for 25 days. HBCx4B mice
(with PIK3CA and NF1 mutation) were treated (i) with PF-
04691502 (MedChem Express®; 10 mg/kg, once daily), five
times a week, for 25 days and (ii) with a combination of oral
PF-04691502 (MedChem Express®; 10 mg/kg, once daily), five
times a week and selumetinib (50 mg/kg, bid; MedChem
Express®), five times a week for 25 days.
Tumor growth was evaluated by measuring two perpendic-
ular tumor diameters with calipers twice a week. Individual
tumor volumes were calculated: V = a × b2/2, where “a” is the
largest diameter, “b” is the smallest diameter. For each tumor,
volumes were expressed in relation to the initial volume as
relative tumor volume (RTV). Tumor growth inhibition (TGI)
of treated tumors vs. controls was calculated as the ratio of
the mean RTV in the treated group to the mean RTV in the
control group at the same time. Statistical significance of TGI
was calculated by a paired Student’s t test by comparing
tumor volumes in the treated and control groups.
Transcriptomic data analysis
Transcriptomic profiling of 61 TNBC PDX was performed by
gene expression arrays. The concentration and integrity/purity
of each RNA sample were measured using RNA 6000 LabChip
kit (Agilent) and the Agilent 2100 bioanalyzer. GeneChip
Human 1.1 ST arrays were hybridized according to Affymetrix
recommendations using WT Expression Kit protocol (Life
Technologies, Carlsbad, CA) and Affymetrix labeling and
hybridization kits. Arrays were normalized according to the
RMA normalization procedure using the Oligo package.19 No
additional human–mouse cross-hybridization filtering were
applied as our xenografts samples contains less than 5% of
mouse cells (percentage determinated using RT-PCR for
quantification of transcripts of the ubiquitous expressed TBP
gene with specific mouse and human primers pairs) and do
not affect expression profiles provided by HuGene1.0 arrays.20
The TNBC molecular subtypes of PDX were determined on
the basis of gene expression data with TNBCtype software
developed by Chen et al.21
Somatic mutation analysis
A total of 61 triple-negative PDXs were analyzed by targeted
NGS of 95 genes, chosen among the most frequently mutated
genes in breast cancer (>1%) and including potential therapeutic
targets (Supporting Information Table S4). NGS primers were
specifically designed on human genome reference (<1% of the
total read are common with mice). NGS was performed on an
Illumina HiSeq2500 sequencer and the genomic variants were
annotated with COSMIC and 1000 genome databases.22 Reads
were aligned using BWA allowing up to 4% of mismatches with
the reference. Only those reads with a mapping quality higher
than 20 were used for variant calling, performed with GATK
UnifiedGenotyper. Genomic alterations included single nucleo-
tide variations of SMGs (i.e., base substitutions and short
insertions/deletions).23 Deleterious genomic alterations were
defined as follows: (i) for oncogenes, only mutations driving to
gain of function were considered (i.e., hotspots missense muta-
tions, in-frame insertions/deletions/splicing described as onco-
genic), (ii) for tumor suppressor genes (TSG), only mutations
driving to loss of function were considered (i.e., biallelic truncat-
ing alterations (nonsense mutations, frameshift insertions/
deletions/splicing) or monoallelic truncating alterations associ-
ated with heterozygous deletion detected by copy number analy-
sis). Variants with low allelic frequency (<5%) or low coverage
(<100×) were excluded from the analysis. No patient’s control
(for constitutional analysis) was used as we reported only patho-
logical variants, validated in literature or public database.
Genomic variants were biologically validated by comparison
with COSMIC, TumorPortal and cBioportal databases (7, 15).
Somatic copy number alteration (SCNA) analysis
PDX were profiled using Affymetrix genomics array: 24 with
SNP 6.0 and 37 with Cytoscan HD array. Genome-wide
copy number analysis was conducted by means of
Affymetrix SNP arrays, as previously described.24,25 SNP 6.0
or Cytoscan HD was processed with 500 and 250 ng of
gDNA as starting material, respectively, as recommended
by the supplier. Raw data were normalized with Genotyping
console (SNP6.0 arrays) or Chromosome Analysis Suite
(Cytoscan HD arrays). Focal amplification of oncogenes
was defined by log ratio >1.58 (six copies per diploid
genome) and maximum size <10 megabases. Biallelic inacti-
vation of TSGs was defined by homozygous deletion or
truncating mutation associated with heterozygous deletion.
Copy number alterations were compared to cBioPortal data
for TCGA breast cancer.26,27 All PDX copy numbers were
represented by the circular binary segmentation algorithm28
as implemented in the DNAcopy package for R using a
minimum width of 3, alpha less than 0.01 and up to 10,000
permutations. Downstream analysis of the sample population
was performed with GISTIC2.029 based on default settings. Com-
parative genomic hybridization (CGH) explorer and CGHcall
were used for visual representation of the results and figures.30
The BRCAness signature was defined with large-scale state tran-
sitions (LST), defined as chromosomal break between adjacent
regions of at least 10 Mb initially described by T. Popova with
Gap methodology.31
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Immunohistochemistry
Immunohistochemistry of PDX. Twenty-eight of the 61 TNBC
PDXs were fixed in 10% neutral buffered formalin, paraffin embed-
ded and hematoxylin–eosin stained. TNBC PDXs were included in
TMA in duplicate. Two cores were picked from each tumor paraf-
fin block using Tissue-Tek Quick-Ray System from Sakura and 6 ×
10 matrix of 2 mm core recipient block; 4 μm TMA sections were
adhered to Superfrost Plus slides (MICROM, Walldorf, Germany).
Rabbit CK5 (Abcam, Cambridge, UK; ab52635, 1/400), CK8/18
(cloneE431-1, Invitrogen, Carlsbad, CA, 1/100), CK14 (Abcam,
ab198167, 1/100), EGFR (Cell Signaling, #4267, 1/100) were used.
Parallel-stained slides with preimmune rabbit IgG were used as
negative controls. Incubation and revelation using the streptavidin–
biotin–peroxidase complex method with DAB as substrate were
performed in a Ventana Medical System (ROCHE, Tucson, AZ)
DXT automat.
Immunohistochemistry of patients. Twenty-eight TN breast
tumors corresponding to PDX were available for the comparison
with PDX’s tumors. Immunostaining was performed according
to previously published protocols.32 Briefly, 4 μm tissue sections
were prepared from a representative sample of the tumor. After
rehydration and antigen retrieval in citrate buffer (10 mM,
pH 6.1), tissue sections were stained for CK5 (BioSB, Santa
Barbara, CA; BSB6602, 1/100), CK8/18 (BioSB, BSB5419, 1/400),
CK14 (Novocastra, Buffalo Grove, IL, NCL-L-LL002, 1/100),
EGFR (Invitrogen, 28–005, 1/200). Staining was revealed with the
Vectastain Elite ABC peroxidase mouse Immunoglobulin G kit
(Vector, Burlingame, CA) using diaminobenzidine (Dako A/S,
Glostrup, Denmark) as chromogen.
Morphology and immunohistochemistry (IHC) of both
patient and PDX tumors were compared by the same histolo-
gist (ML). The percentage of positive tumors was scored by the
percentage of cells showing positive staining and staining intensity
was scored on a scale from 0 to 3 (0 = no specific staining; + =
weak; ++ = moderate; +++ = strong). IHC defined basal-like phe-
notype with positivity for basal cytokeratin (CK5 and/or CK14)
and/or the presence of EGFR marker. Basal CK are absent and
luminal cytokeratin (CK18) is positive in androgen or apocrine
subtype.33
Statistical analysis
Metastasis-free survival (MFS) was determined as the interval
between diagnosis and detection of the first distant metastasis.
Survival distribution was estimated with the Kaplan–Meier
method. The proportion of transcriptomal TNBC subgroup
was compared to a χ2 test. The proportion of genomic alter-
ations between PDX and TCGA was compared to a χ2 test or
Fisher’s exact test, as appropriate.
Results
Clinicopathological characteristics of TNBC patients
The clinical and pathological characteristics of the patients
corresponding to the established TNBC PDXs were analyzed
to determine whether they reflected the heterogeneity of TNBC.
This cohort of 61 patients presented the usual characteristics of
TNBC34 (Supporting Information Tables S1 and S2). Mean age
at diagnosis was 56 years. TNM staging mostly corresponded
to T2 (59.4%), N0 (61.7%) with a small percentage of synchro-
nous metastasis (10%). Fifty-seven percent of patients were
treated by mastectomy and 79.7% by lymphadenectomy. This
proportion can be explained by the extended period of PDX
establishment (2000–2017). In 2000s, primary chemotherapy
and node biopsy were performed less frequently. Histologically,
90% of tumors were invasive ductal carcinoma of no special
type (NST). Six tumors were characterized by a rare histology:
one micropapillary, one apocrine and four with metaplastic dif-
ferentiation (squamous, fusiform or chondroid). One-third
(32.7%) of tumors presented emboli and a majority had a high-
SBR histological grade. The majority of patients received
sequential chemotherapy (anthracycline then taxane) as adju-
vant or neoadjuvant therapy. All patients who underwent
tumorectomy also received adjuvant radiotherapy. Some
patients treated by mastectomy received radiotherapy
according to the Institut Curie guidelines. Five-year metastasis-
free survival (MFS) was 61% in this TNBC cohort (data not
shown).
Gene expression analysis and Lehmann classification
To analyze TNBC heterogeneity in terms of gene expression,
we generated transcriptomic profiles by gene expression arrays
and classified the PDX models among the various TNBC
molecular subtypes, as defined by Lehmann et al.,6 using the
TNBCtype tool.21 The distribution of the various subtypes in
PDX was then compared to the TNBC classification based on
the TCGA and METABRIC cohorts8,9 (Fig. 1). The frequencies
of the various TNBC subtypes were similar except for IM and
BL1 subtypes. IM subtype was underrepresented in this cohort
of TNBC PDX: 3.5% vs.18 and 20% in the TCGA and META-
BRIC cohorts, respectively (p < 0.005). BL1 subtype was overrepre-
sented in this series of PDX: 31% vs.17 and 19% in the TCGA and
METABRIC cohorts, respectively (p = 0.02 and 0.05, respectively).
Histopathologic and immunophenotypic characterization
The morphology and IHC profile of 28 paired tumors were
analyzed in order to compare the histology of PDX and
patient tumors. Microscopic examination of hematoxylin and
eosin (H&E) stained histological sections demonstrated that
the original tumor characteristics were preserved in the PDX.
Mouse xenografts displayed strong histological similarity with
the clinical specimens including tumor cellularity, histo-
pronostic grade (tubule and gland formation, nuclear pleo-
morphism and mitotic counts; Fig. 2). Xenograft tumors also
retained the histopathological features of the original patient
tumors in particular for rare subtypes such as metaplastic
breast cancer (e.g., squamous cell carcinoma or metaplastic car-
cinoma with chondroid differentiation), indicating the same pat-
tern of differentiation capacity (Fig. 3). Immunochemistry with
4 Molecular heterogeneity in TNBC PDX
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epithelial markers (CK5, CK14 and CK8/18) and a specific bio-
marker (EGFR) was used to define a basal-like phenotype
(Fig. 2 and Table S5). The majority of TNBC PDX (92%) pres-
ented a basal-like phenotype (EGFR and/or CK5 and/or CK14
positive). As expected, HBCx2, a LAR subtype tumor, expressed
no basal cytokeratin but the luminal CK8/18.
Genomic alteration
The genomes of 61 TNBC PDX were analyzed by targeted
NGS of 95 genes and CGH arrays. Data of SMGs and SCNAs
are detailed in Figure 4. Details of the 65 SMGs are described
in Table S6. As expected, the majority of TNBC PDX pres-
ented an alteration of the TP53 gene (50.8%; 82.1% for the
TCGA and 82.7% for the METABRIC cohort). Homozygous
deletion of CDKN2A (9.8%) or RB1 (4.9%) were the other most
common cell cycle anomalies (in our targeted analysis). Receptor
Tyrosine Kinase (RTK), PI3K and MAPK pathways were altered
in 42.6, 40.9 and 32.7% of TNBC PDX, respectively. Some SMGs
or SCNAs with possible targeted therapies were present in this
cohort. PIK3CA was the second most frequently altered gene
in the PI3K pathway (18% including 10% of mutations and
8% of focal amplifications). Other effectors of this pathway
were also altered: AKT1 (4.9% of activating mutations and
4.9% of focal amplifications) and PTEN (11.5% of biallelic
inactivations). This pathway was more frequently altered in
BL2 (100%), LAR (80%) and MSL (75%) subtypes. Focal
amplifications of FGFR1 (8.1%), FGFR4 (8.1%) and IGF1R
(6.5%) were the three major oncogenes altered in the RTK
pathway. Focal amplifications of KRAS (13.11%), BRAF
(6.6%) and inactivating mutations of NF1 (4.9%) were
observed in the MAPK pathway. BRCA1 (13.1%) and BRCA2
(3.3%) mutations were the most common alterations in the
DNA repair pathway. All 10 patients BRCA1 or BRCA2
mutated tumors presented a BRCAness signature as identified
by CGH profiles. Comparison with TNBC tumors of the
TCGA database (details in Supporting Information Table S7)
showed a similar distribution of the major genomic alteration
for SCNAs and SMGs. However, some RTK or MAPK path-
way alterations were more frequent in PDX among which
some are potentially actionable, such as KRAS, BRAF and
FGFR4 (p < 0.05) focal amplification (Fig. 5a and 5b). Focal
amplification of DDR2, a collagen receptor kinase was also
overrepresented (but not significantly) in PDX (16.4% vs.
6.7% in TCGA, p = 0.06). The global copy number profile of
this cohort (Fig. 5c) highlights the classical characteristic of
TNBC: 8q24 (MYC) focal amplification (>50% in our cohort),
1q and 10p gain, 8p and 5q losses. Eighty-eight percent of
PDX models had an actionable alteration and 54% presented
an association of at least two actionable alterations, particu-
larly in the PI3K and MAPK pathways with possible targeted
therapies combination (Supporting Information Table S8).
SMG analysis of PDX included 44 ER+ and/or HER2+ PDX
breast cancers, established by our group since 2003. The
Figure 1. Repartition of the Lehmann subtype (%) in our 61 TNBC PDX
and TNBC of TCGA and METABRIC cohort. Abbreviations: BL1, basal-like
1; BL2, basal-like2; IM, immunomodulatory; M, mesenchymal; MSL,
mesenchymal stem like; LAR, luminal androgen receptor; UNS,
unclassified.
Figure 2. Comparison of morphology and IHC between patient and PDX.
Coussy et al. 5
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distribution of mutations in ER+ PDX highlighted four major
mutated genes: PIK3CA (27%), TP53 (24%), MAP3K1 (11%)
and GATA3 (8%; Supporting Information Table S6). These
predominant genes in ER+ breast cancer have been largely
described in the literature.8
Testing of two targeted therapies, alone and in
combination, in TNBC PDX
MAPK and PI3K pathways represented two major targetable
pathways in this cohort. Consistent with this notion, we tested
the antitumor activity of two promising inhibitors of these path-
ways: selumetinib (a MEK inhibitor) and PF-04691502 (a dual
PI3KCA/mTOR inhibitor) in PDX with genomic alterations in
PI3K and MAPK pathways. These two PDXs are resistant to
chemotherapies commonly used in TNBC (anthracycline, taxane
and platine; Supporting Information Figure S1). Figure 6a shows
the antitumor activity of selumetinib in the HBCx-92 PDX, har-
boring a NRAS hotspot mutation (p.Q61K). After 25 days of
treatment, selumetinib (a MEK inhibitor) induced significant
TGI (85%). As some PDX presented multiple targetable alter-
ations, PF-04691502 monotherapy was initially tested, followed
by a combination of two targeted therapies in HBCx4B (PIK3CA
hotspot mutation, p.E545K and NF1 inactivating mutation, p.
K2631 fs, associated with loss of heterozygosity) with PF-
04691502 and selumetinib (Fig. 6b and 6c). Monotherapy
induced a TGI of 70% without complete response. Combination
therapy was significantly superior to monotherapy (TGI of 90%)
and two mice obtained a complete response (Fig. 6d).
Discussion
We report the largest cohort of clinically annotated TNBC PDX,
illustrating the genomic, transcriptomic and morphologic hetero-
geneity of TNBC. Several other authors have described genomic
alterations in small cohorts of TNBC PDX, including description
of morphological and genomic fidelity with the patient’s tumor
and possibility to identify efficient treatment and predictive bio-
markers.12,16,35 The primary objective of transcriptomic classifica-
tions is to identify subtypes with biologic drivers in order to
Figure 3. Morphological comparison between patient’s tumor and PDX for (a) invasive carcinoma of no special type (NST) both patient’s
tumor and PDX have large nuclei and no evidence of glandular differentiation, and a high proliferative rate; (b) metaplastic carcinoma with
mesenchymal differentiation: areas of chondroïd and myxoïd differentiation are observed in both patient tumor and PDX; (c) squamous cell
carcinoma is characterized by cystic cavity lined by squamous epithelium. Typical squamous cells with keratinizing are observed in PDX
tumor.
6 Molecular heterogeneity in TNBC PDX
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Figure 4. Details of SCNAs and SMGs of 61 TNBC PDX.
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guide personalized treatment. By comparing the distribution of
TNBC PDX according to Lehmann’s classification, with TNBC
of TCGA8 and METABRIC data,9 the distribution of the various
data sets was similar, except for IM (underrepresented in our
cohort) and BL1 subtype (overrepresented in our cohort). As the
IM subtype is characterized by expression of immunity genes,
most of which are expressed by immune cells, the low frequency
of this subtype in PDX is only to be expected and can be
explained by the loss of human stroma in PDX models. BL1 sub-
type is overrepresented in our PDX cohort, probably because the
majority of IM subtypes were reclassified in the BL1 subgroup as
described in Lehmann’s second classification.36 Transcriptomic
Figure 5. Comparison of SCNAs (a) and SMGs (b) for the most frequently altered genes between TN PDX and TCGA C: representation of global
alteration of copies numbers of TN PDX.
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classifications are not used in clinical practice, but stress the impor-
tance of selection of the TNBC subtype before prescribing targeted
therapy. However, except for the LAR and mesenchymal subtypes,
it is difficult to demonstrate a specific correlation between trans-
criptomic subtype and response to targeted therapy.8,37
In our study, the most frequently altered genes in TNBC are
comparable to those described in the TCGA or METABRIC.
Moreover, our presentation of global copy number alterations
highlights the specific characteristics of TNBC: 8q24 (MYC) focal
gain, 1q, 10p gain and 8p, 5q loss.8 Some transcriptomic sub-
types in this cohort harbored specific somatic mutations already
described in other studies6,37 LAR subtype corresponds to the
luminal repertoire of genomic alterations: the most frequent
mutations are PIK3CA and AKT1 (40%, 2/5) and the less fre-
quent mutations are TP53 (20%). BL1 and BL2 present a high
percentage of TP53 mutations (55.5 and 75%, respectively).
As expected, the PI3K pathway was frequently altered in
the present cohort: 40.9% of PDX presented at least one geno-
mic alteration in this pathway. PIK3CA mutation and loss of
PTEN were the most frequent alterations. This pathway was
particularly altered in LAR, BL2 and MSL subtypes, as
described in several other studies6,36 and inhibitors of this
pathway could be useful in these particular subtypes. We have
previously shown that everolimus induced a significant response
in 7 out of 15 TNBC PDX, irrespective of the PIK3CA muta-
tional status.38 In another study, seven TNBC PDX treated with
rapamycin (mTOR inhibitor), showed a marked growth inhibi-
tion, supporting the value of this treatment in TNBC.39 Few
clinical data are available concerning the PI3K pathway inhibitor
in TNBC40 and various studies have tested specific PI3K inhibi-
tors and have tried to identify biomarkers (SAFIR study,
NCT02299999). Dual PI3K/mTOR inhibitor (PF-04691502)
presents an advantage by ensuring more complete suppression
of the pathway by inhibiting PI3K as well as mTORC1 and
mTORC2 and theoretically abrogates possible negative feedback
loops caused by inhibition of mTORC1 alone.41 In our study,
we show that PF-04691502 inhibits tumor growth in our PDX
with PIK3CA mutation, emphasizing the value of this type of
specific PI3K pathway inhibition. The MAPK pathway pres-
ented rare but targetable alterations of oncogenic drivers,
suggesting that targeting this pathway may be an option for
TNBC tumors. Few published data are available concerning
MEK inhibitors in TNBC. Trametinib was tested in eight PDX
with a high range of MEK/ERK phosphorylation: the best
response was observed in the PDX with the most highly acti-
vated MAPK pathway.35 Interestingly, in a phase Ib trial in
patients with solid tumors (n = 31) treated with gemcitabine
and trametinib, the only complete response to therapy was
Figure 6. (a) Treatment of HBCx92 with selumetinib; (b) treatment of HBCx4B by PF-04691502; (c): treatment of HBCx4B with a combination
of selumetinib+PF-0469150; (d) Waterfall plots representing the percent change in tumor for each mouse of HBCx4B treated with
selumetinib, PF-04691502 and combination of selumetinib+PF-046915. Mean of RTV  SD. n = 3 mice per group (a and b) and n = 8 mice
per group (c and d). *Significant difference, p < 0.01 (Mann–Whitney test), p < 0.05.
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observed in a patient with TNBC.42 Selumetinib was tested in
one model of breast cancer xenograft with regression of lung
metastasis.43 A MAPK inhibitor is currently under clinical
investigation in TNBC with a specific targetable alteration of the
MAPK pathway (selumetinib in the metastatic setting, SAFIR02,
NCT02299999; or neoadjuvant setting, NCT02685657). Here,
we showed that selumetinib markedly reduced tumor growth in
our selected PDX with NRAS mutation confirming the value of
this drug in selected tumors.
Our study provides evidence of the multiple alterations
present in each tumor (54% presented at least two targetable
alterations) which can have important clinical implications: (i)
it is essential to identify patients likely to benefit from effective
targeted therapies by means of genomic biomarkers (ii) two
inhibitor monotherapies were tested in our study in
chemoresistant PDX with specific alterations, resulting in sig-
nificant growth inhibition but the combination of a dual
PI3K/mTOR inhibitor and MEK inhibitor provided very
encouraging results, with a better response than mono-
therapies and 30% of complete response.
Conclusion
Our study shows that PDX reproduce the molecular heteroge-
neity of TNBC. This subtype is characterized by marked het-
erogeneity, explaining why TNBC “divides and rules.” The
high percentage of tumors with concomitant targetable anom-
alies in our cohort emphasizes the various possibilities of
combination therapy, particularly between PI3K, MAPK, cell
cycle and DNA repair pathways, as recently described in
TCGA.44 These results are very encouraging to continue test-
ing various targeted therapies and combination in our models
in order to develop new treatments and combination
in TNBC.
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